Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure drug dapagliflozin under Real-World microscope in greece

NCT ID NCT05635331

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study in Greece observed 257 adults with heart failure who were prescribed dapagliflozin as part of their routine care. Researchers tracked how long patients stayed on the drug, any changes in their other heart medications, and how their quality of life changed over time. The goal was to understand how this approved medication works in everyday practice, outside of a controlled clinical trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dapagliflozin
What this could lead to
If successful, this study could provide real-world insights into how dapagliflozin is used and tolerated in everyday heart failure care, potentially improving treatment guidelines.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient selection and other factors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

257 people

The number who actually took part.

Started

Dec 2022

Finished

Dec 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who have received treatment with dapagliflozin for Heart Failure with reduced Ejection Fraction will be eligible for enrolment by physicians from outpatient and inpatient settings. Eligible patients will be selected after they have been identified in paper or electronic medical records by the participating investigator. Consecutive patients prescribed dapagliflozin should be identified by the investigator and, unless failing to meet the inclusion and exclusion criteria, should be invited to participate. Patients will only be enrolled after they have given consent to participate in the study. In all cases, the decision to treat a patient with dapagliflozin must be made prior to the decision to enroll the patient into the study. To help ensure this, at least 14 days must have elapsed (but no more than 60 days) from the date of initiation of dapagliflozin before a patient can be enrolled.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years as of study index date; the study index date is the date of initiation of treatment with dapagliflozin * Patient received/receiving treatment with dapagliflozin for Heart Failure with reduced Ejection Fraction in accordance with the local dapagliflozin product label * Signed and dated informed consent prior to enrolment in the study Exclusion Criteria: * Patient is enrolled less than 14 days or more than 60 days following initiation of dapagliflozin * Prior treatment with dapagliflozin or other Sodium Glucose co-transporter 2 inhibitor treatment * Initiation of dapagliflozin outside of local Heart Failure label * Diagnosis of Type 1 diabetes prior to enrolment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

Contacts and locations

Locations

  • Research Site

    Alexandroupoli, 68100, Greece

  • Research Site

    Athens, 11526, Greece

  • Research Site

    Athens, 11527, Greece

  • Research Site

    Athens, 11528, Greece

  • Research Site

    Athens, 12462, Greece

  • Research Site

    Athens, 14233, Greece

  • Research Site

    Athens, 17674, Greece

  • Research Site

    Chania, 73300, Greece

  • Research Site

    Heraklion, 71409, Greece

  • Research Site

    Ioannina, 45445, Greece

  • Research Site

    Ioannina, 45500, Greece

  • Research Site

    Pátrai, 26504, Greece

  • Research Site

    Thessaloniki, 54636, Greece

  • Research Site

    Thessaloniki, 54642, Greece

  • Research Site

    Thessaloniki, 56429, Greece

  • Research Site

    Thessaloniki, 57010, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.